🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Shortwave Intervention for Diabetic Peripheral Neuropathy.

RecruitingNAAges 18 Years - 85 YearsAllChongqing Medical University
NCT07625007 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a single-center, randomized, single-blind, sham-controlled clinical trial aimed at evaluating the efficacy and safety of shortwave therapy administered for five consecutive days in the treatment of diabetic peripheral neuropathy. The study plans to enroll 202 patients, who will be randomly assigned in a 1:1 ratio to either the shortwave therapy group (20 minutes daily for five consecutive days) or a sham treatment group with an identical appearance. The primary efficacy endpoint is the remission rate of the Toronto Clinical Scoring System score one month after treatment (a decrease of ≥1 point). Secondary endpoints include short-term efficacy, pain visual analog scale scores, quality of life scores, and safety indicators. The study hypothesizes that shortwave therapy can significantly improve neurological symptoms, with an expected remission rate of 65% in the treatment gro

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 1\. Aged 18-85 years, regardless of gender, with the ability to act independently; * 2\. Appearance of neuropathic symptoms or signs at the time of or after the diagnosis of diabetes, meeting the following criteria: presence of DPN symptoms (numbness, tingling, burning, cold, pain), with or without signs (abnormalities in any of ankle reflex, vibration sense, pinprick sensation, temperature sensation, or pressure sensation); * 3\. Able to complete the TCSS assessment; * 4\. Understands the entire trial process, voluntarily participates in the study, and signs the informed consent form. * 5\. Patients who did not respond to adequate treatment with mecobalamin and other medications. Exclusion Criteria: * 1\. Peripheral neuropathy caused by other reasons (such as lumbar spine lesions, vitamin B12 deficiency, uncontrolled hypothyroidism, alcohol intoxication, drug neurotoxicity, Guillain-Barré syndrome, etc.); * 2\. Hemorrhagic diseases, malignant tumors; * 3\. History of below-knee amputation; * 4\. Skin damage, infection at the treatment site, or presence of metal implants, pacemaker; * 5\. Combined severe heart, liver, or kidney dysfunction (e.g., eGFR \< 15 ml/min/1.73m²), or cognitive impairment preventing cooperation; * 6\. Pregnancy, breastfeeding, or planning pregnancy; * 7\. Participation in other interventional clinical trials within the past 3 months; * 8\. Combined severe psychiatric disorders; * 9\. Other conditions assessed by the investigator that prevent completion of the trial; * 10\. Poor compliance.
💊

What it tests

  • Short-Wave Diathermy
  • Placebo treatment group
📍

Where

1 site
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy